Figure 4.
Figure 4. Tumor-to-normal organ ratios for conventional directly labeled 111In-DOTA-1F5 Ab or 111In-DOTA biotin pretargeted with B9E9 (scFv)4-SA fusion protein, 1F5 (scFv)4-SA fusion protein, or 1F5 Ab-SA chemical conjugate. Mice were treated as described in Figure 3. Tumor-to-normal organ ratios of administered 111In-DOTA-1F5 or 111In-DOTA biotin are shown for the 24-hour time point after injection of radioactivity. 1F5 (scFv)4SA fusion protein (▦), B9E9 (scFv)4SA fusion protein (▪), 1F5 Ab-SA chemical conjugate (▨), directly labeled conventional 111In-DOTA-1F5 Ab (□). P values represent differences between the 1F5 (scFv)4-SA fusion protein and directly labeled DOTA-1F5 Ab.

Tumor-to-normal organ ratios for conventional directly labeled 111In-DOTA-1F5 Ab or 111In-DOTA biotin pretargeted with B9E9 (scFv)4-SA fusion protein, 1F5 (scFv)4-SA fusion protein, or 1F5 Ab-SA chemical conjugate. Mice were treated as described in Figure 3. Tumor-to-normal organ ratios of administered 111In-DOTA-1F5 or 111In-DOTA biotin are shown for the 24-hour time point after injection of radioactivity. 1F5 (scFv)4SA fusion protein (▦), B9E9 (scFv)4SA fusion protein (▪), 1F5 Ab-SA chemical conjugate (▨), directly labeled conventional 111In-DOTA-1F5 Ab (□). P values represent differences between the 1F5 (scFv)4-SA fusion protein and directly labeled DOTA-1F5 Ab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal